Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904293 · ClinicalTrials.gov registry record · NA
Genotype-Guided Warfarin Therapy Trial
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 109
- Enrollment target
NCT00904293 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 109 participants.
The verdict
NCT00904293, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 109 participants
- Enrollment target
Study Summary
The purpose of the investigators' study is to determine the clinical utility of a warfarin-dosing algorithm that incorporates genetic information (VKORC1 and CYP2C9 alleles) for adult patients initiating warfarin therapy.
Interventions
- OTHER Genotype-guided dose determination
- OTHER Non-genotype guided warfarin dosing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00904293
The ClinicalTrials.gov registry entry for NCT00904293 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Genotype-guided dose determination is the first listed.
NCT00904293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00904293 about?
NCT00904293 is a clinical study titled "Genotype-Guided Warfarin Therapy Trial". The purpose of the investigators' study is to determine the clinical utility of a warfarin-dosing algorithm that incorporates genetic information (VKORC1 and CYP2C9 alleles) for adult patients initiating warfarin therapy.
What is the current status of trial NCT00904293?
This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2008-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00904293?
The interventions under investigation include: Genotype-guided dose determination (OTHER), Non-genotype guided warfarin dosing (OTHER).
Who is sponsoring clinical trial NCT00904293?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.